美股异动丨诺华制药盘前涨近2%,布局过敏性疾病新靶点

格隆汇
Dec 09, 2025

诺华制药(NVS.US)盘前涨近2%,报132.73美元。消息面上,诺华制药与英国生物技术公司 Relation Therapeutics达成一项高达逾17亿美元的交易,以帮助寻找治疗过敏性疾病的药物靶点。该交易旨在将诺华制药在免疫皮肤病学方面的专业知识与Relation的药物发现人工智能平台相结合,后者借助包括人体组织在内的患者数据来揭示疾病表现的遗传基础。(格隆汇)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10